Download Free Glaxo Book in PDF and EPUB Free Download. You can read online Glaxo and write the review.

This 1992 study of Glaxo, from its beginnings to 1962, examines the global operations of this pharmaceutical company.
This book highlights research-based case studies in order to analyze the wealth created in the world’s largest mergers and acquisitions (M&A). This book encourages cross fertilization in theory building and applied research by examining the links between M&A and wealth creation. Each chapter covers a specific case and offers a focused clinical examination of the entire lifecycle of M&A for each mega deal, exploring all aspects of the process. The success of M&A are analyzed through two main research approaches: event studies and financial performance analyses. The event studies examine the abnormal returns to the shareholders in the period surrounding the merger announcement. The financial performance studies examine the reported financial results of acquirers before and after the acquisition to see whether financial performance has improved after merger. The relation between method of payment, premium paid and stock returns are examined. The chapters also discuss synergies of the deal-cost and revenue synergies. Mergers and acquisitions represent a major force in modern financial and economic environment. Whether in times of boom or bust, M&As have emerged as a compelling strategy for growth. The biggest companies of modern day have all taken form through a series of restructuring activities like multiple mergers. Acquisitions continue to remain as the quickest route companies take to operate in new markets and to add new capabilities and resources. The cases covered in this book highlights high profile M&As and focuses on the wealth creation for shareholders of acquirer and target firms as a financial assessment of the merger’s success. The book should be useful for finance professionals, corporate planners, strategists, and managers.
A casebook that discusses all the mega mergers and acquisitions in terms of value, that have happened in different industry sectors such as pharmacy, technology, telecommunications, media and entertainment, electrical and electronics, energy, finance, consumer goods, metals, and automobile and airlines.
Many health care providers are frequently dealing with problems related to the identification and interpretation of medicines and prescriptions of foreign origin. Health authorities, customs and travel agencies also encounter such problems, which are related to the increasing mobility of the European population. Thus the need for a European Drug Index is obvious. The EDI provides extended information for practitioners confronted with the enormous number of drug names available on the European pharmaceutical market. This market is increasing due to the rapidly changing palette of countries and economic restrictions in Europe. The listings have been derived from drug data sources from the increased number of participating countries in this second edition. Each item starts with a trade name, in alphabetical order, followed by (depending on the original source) dosage forms, strength, volume (if applicable), and generic name(s) of the active principle(s) in a random sequence. The item is concluded by the Anatomical Therapeutic Chemical (ATC) classification (when made available by the original source) and a code for the country of origin.
For 40 years, the Index Nominum has been the indispensable standard reference work on medications, brand names, synonyms, chemical structures, and therapeutic classes of substances, providing orientation in the international pharmaceutical market. This Seventeenth Edition has been completely revised, restructured, and given a new layout. It now includes each active substance's German, French, Spanish, and Latin names, anatomical therapeutical chemical classification (ATC) code, and molecular mass. With its clear layout, visual aids, and easily searchable information, the Index Nominum 2000 provides all the essentials at your fingertips.
With transnationals now of immense significance to many economies and thus seeming to have immense leverage over host governments, this book looks at what can be done to influence the behaviour of these corporations. With a case study of Glaxo.